BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22507776)

  • 1. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
    Abdel-Wahab O
    Hematology; 2012 Apr; 17 Suppl 1():S39-42. PubMed ID: 22507776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
    Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
    Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
    Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomics in acute myeloid leukemia: from identification to personalization.
    Martin JM; Winer ES
    R I Med J (2013); 2015 Nov; 98(11):27-30. PubMed ID: 26517252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
    Falini B; Sportoletti P; Brunetti L; Martelli MP
    Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
    Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
    Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
    Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
    Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The significance of the epigenetics modifying gene mutations in acute myeloid leukemia].
    Wakita S; Yamaguchi H
    Nihon Rinsho; 2014 Jun; 72(6):1026-32. PubMed ID: 25016799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of novel mutations in epigenetic modifiers in AML.
    Abdel-Wahab O; Patel J; Levine RL
    Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking the gold standard for recurrent DNA mutations detection in acute myeloid leukemia.
    Novaretti MC
    Eur J Haematol; 2016 Feb; 96(2):109-10. PubMed ID: 26110968
    [No Abstract]   [Full Text] [Related]  

  • 11. ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.
    Paschka P; Schlenk RF; Gaidzik VI; Herzig JK; Aulitzky T; Bullinger L; Späth D; Teleanu V; Kündgen A; Köhne CH; Brossart P; Held G; Horst HA; Ringhoffer M; Götze K; Nachbaur D; Kindler T; Heuser M; Thol F; Ganser A; Döhner H; Döhner K
    Haematologica; 2015 Mar; 100(3):324-30. PubMed ID: 25596267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
    Zhu C; Ma Y; Xu XP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
    Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
    Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and Clinicopathologic Features of RUNX1 Mutations in Patients With Acute Myeloid Leukemia Not Otherwise Specified.
    You E; Cho YU; Jang S; Seo EJ; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park YM; Lee JK; Park CJ
    Am J Clin Pathol; 2017 Jul; 148(1):64-72. PubMed ID: 28927163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How do novel molecular genetic markers influence treatment decisions in acute myeloid leukemia?
    Patel JP; Levine RL
    Hematology Am Soc Hematol Educ Program; 2012; 2012():28-34. PubMed ID: 23233557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genome-wide analysis of AML and MDS].
    Ogawa S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():113-8. PubMed ID: 23133938
    [No Abstract]   [Full Text] [Related]  

  • 18. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
    Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
    Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.
    Im AP; Sehgal AR; Carroll MP; Smith BD; Tefferi A; Johnson DE; Boyiadzis M
    Leukemia; 2014 Sep; 28(9):1774-83. PubMed ID: 24699305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant DNMT3A in acute myeloid leukemia: guilty of inducing genetic instability?
    Zebisch A; Hoefler G; Quehenberger F; Wölfler A; Sill H
    Leukemia; 2013 Aug; 27(8):1777-8. PubMed ID: 23417030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.